Lixisenatide vs UBT251

Head-to-head comparison of Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) and UBT251 (UBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyLixisenatideUBT251
CategoryWeight ManagementWeight Management
Full NameExendin-4-derived GLP-1 receptor agonistUBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist
Molecular Weight4858 DaN/A
Half-Life2-4 hoursApproximately 1 week
Amino Acids44N/A
Typical Dose10-20 mcg dailyInvestigational; no established human dose
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count4008
Research StatusApprovedPre-clinical

Lixisenatide Benefits

  • postprandial glucose control
  • modest weight loss
  • appetite reduction
  • short-acting option

UBT251 Benefits

  • weight reduction
  • improved satiety
  • enhanced energy expenditure
  • better insulin sensitivity

Lixisenatide Dosing

10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day

UBT251 Dosing

once-weekly subcutaneous injection|dose escalation in studies|maintenance after tolerability assessment

Lixisenatide Side Effects

  • nausea
  • vomiting
  • hypoglycemia when combined with insulin

UBT251 Side Effects

  • nausea
  • diarrhea
  • fatigue

Research Overview

Lixisenatide

Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.

UBT251

Published work supports strong anti-obesity activity in preclinical models, with translation into human studies still emerging. The compound remains investigational and is best characterized as an early multi-agonist program.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Lixisenatide stacks with:

basal-insulinmeal-plan

UBT251 stacks with:

metforminorlistat
GLP-1RAshort-actingpostprandial-controlweight-loss-adjacentglp1gipglucagontriagonistweight-management